Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover StudyXue Ge, Michael A. Eldon, Lin Lü et al.|Pain Medicine|2019Cited by 9
PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.Daniel A. Vaena, James K. Schwarz, Jorge Chaves et al.|Journal of Clinical Oncology|2018Cited by 3